OKG 0502
Alternative Names: OKG-0502Latest Information Update: 15 Jan 2024
At a glance
- Originator Okogen
- Class Antineoplastics; Antivirals; Decongestants; Eye disorder therapies; Ribonucleases
- Mechanism of Action Apoptosis stimulants; Protein synthesis inhibitors; Ribonuclease stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Infectious conjunctivitis
Most Recent Events
- 10 Oct 2023 Discontinued - Clinical-Phase-Unknown for Infectious conjunctivitis (Ophthalmic) (Okogen pipeline, October 2023)